Company
PolyPid Ltd.
Right Where Care Begins
Also known as Polypid
- Business model
- B2B
- Legal name
- Polypid Ltd.
Claim, correct or request removal
Record updated 28 September 2026
About
PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care, improving outcomes across surgical care, metabolic diseases, and beyond.
Funding snapshot
- Total raised
- $125MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $26.7M2025-06-16
Funding rounds
- Round, 2025
- $26.7M2025-06-16, SEC form D sold, 20 investors
- Round, 2024
- $14.5M2024-12-26, SEC form D sold, 12 investors
- Round, 2024
- $14.2M2024-08-06, SEC form D sold, 17 investors
- Round, 2024
- $35M2024-01-09, SEC form D sold, 20 investors
- Round, 2019
- $26.9M2019-06-28, SEC form D sold, 361 investors
- Round, 2016
- $8.1M2016-02-04, SEC form D sold, 8 investors
Products
- Web
- D-PLEX 100
Loading relationship preview